Articles tagged with: Bispecific Antibodies

Press Releases»

[ by | Oct 8, 2020 6:00 am | Comments Off ]
Cytovia Therapeutics Partners With Inserm To Develop Selective CD38 NK Therapeutics And Offer New Treatment Options For Multiple Myeloma Patients

New York, NY and Paris, France (Press Release) – Cytovia Thera­peutics ("Cytovia"), an emerging bio­pharma­ceu­tical com­pany, an­nounces to­day that it has entered a re­search and licensing agree­ment with Inserm to de­vel­op NK engager bi-specific anti­bodies and iPSC CAR NK cell ther­apy targeting CD38, a key marker of mul­ti­ple myeloma. The licensing agree­ment has been negotiated and signed by Inserm Transfert, the private sub­sid­i­ary of Inserm, on behalf of Inserm (the French National In­sti­tute of Health and Medical Re­search) and its academic part­ners. Cytovia is licensing Inserm's CD38 anti­body and Chimeric Antigen Receptor (CAR) …

Read the full story »

Press Releases»

[ by | Oct 5, 2020 6:30 am | Comments Off ]

Fifth in­dus­try col­lab­o­ration to eval­u­ate niro­gace­stat as a BCMA po­ten­ti­ator across modalities

SpringWorks Therapeutics Announces Clinical Collaboration With Pfizer Inc. To Evaluate Nirogacestat In Combination With PF‐06863135 In Patients With Relapsed Or Refractory Multiple Myeloma Stamford, CT (Press Release) – Spring­Works Thera­peutics, Inc. (Nasdaq: SWTX), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on devel­op­ing life-changing med­i­cines for patients with severe rare dis­eases and can­cer, to­day an­nounced that the com­pany has entered into a clin­i­cal trial col­lab­o­ration agree­ment with Pfizer Inc. (NYSE: PFE) to eval­u­ate Spring­Works Thera­peutics’ inves­ti­ga­tional gamma se­cre­tase in­hib­i­tor (GSI), niro­gace­stat, in com­bi­na­tion with Pfizer’s anti-B-cell maturation an­ti­gen (BCMA) CD3 bispecific anti­body, PF‐06863135, in patients with re­lapsed or re­frac­tory mul­ti­ple myeloma.

Gamma se­cre­tase in­hib­ition prevents the cleavage and shedding of BCMA from the surface of myeloma cells. In pre­clin­i­cal …

Read the full story »

Press Releases»

[ by | Sep 14, 2020 6:30 am | Comments Off ]

Third col­lab­o­ration to eval­u­ate niro­gace­stat in com­bi­na­tion with BCMA ther­a­pies across modalities

SpringWorks Therapeutics Announces Clinical Collaboration With Janssen To Evaluate Nirogacestat In Combination With Teclistamab In Patients With Relapsed Or Refractory Multiple Myeloma Stamford, CT (Press Release) – Spring­Works Thera­peutics, Inc. (Nasdaq: SWTX), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on devel­op­ing life-changing med­i­cines for patients with severe rare dis­eases and can­cer, to­day an­nounced that the com­pany has entered into a clin­i­cal col­lab­o­ration and supply agree­ment with Janssen Bio­tech, Inc. (Janssen) to eval­u­ate Spring­Works Thera­peutics’ inves­ti­ga­tional gamma se­cre­tase in­hib­i­tor (GSI), niro­gace­stat, in com­bi­na­tion with Janssen’s bispecific anti­body targeting B-cell maturation an­ti­gen (BCMA) and CD3, teclistamab, in patients with re­lapsed or re­frac­tory mul­ti­ple myeloma.

Gamma se­cre­tase in­hib­ition prevents the cleavage and shedding of BCMA from the surface of myeloma …

Read the full story »

Press Releases»

[ by | Nov 6, 2019 8:00 am | Comments Off ]
Teneobio's Lead Candidate, TNB-383B, Receives Orphan Drug Designation From The FDA For The Treatment Of Multiple Myeloma

Newark, CA (Press Release) – Teneobio, Inc., a clin­i­cal-stage bio­technology com­pany devel­op­ing engi­neered bispecific anti­bodies for the treat­ment of cancer announced today that it has re­ceived orphan drug desig­na­tion by the U.S. Food and Drug Admin­istra­tion (FDA) for the treat­ment of multiple myeloma.

“New and better treat­ment options are needed for multiple myeloma. While there are a number of BCMA-targeting agents cur­rently in clin­i­cal devel­op­ment, TNB-383B, an anti-BCMAxCD3 cur­rently in Phase I, is a bispecific com­prised of a unique T-cell engager designed to maximize the thera­peutic window for this class of drugs,” said …

Read the full story »

Press Releases»

[ by | Oct 17, 2019 8:30 am | Comments Off ]
Teneobio And Selexis Expand Relationship With Three Commercial License Agreements For Multi-Specific Antibody Candidates In Oncology

Geneva, Switzerland and Newark, California (Press Release) – Selexis SA and Teneobio, Inc. announced today that they have signed three commercial license agree­ments (CLAs) for the devel­op­ment of Teneobio’s Human Heavy-Chain Antibodies (UniAbs™), a new class of multi-specific biologics, for the treat­ment of multiple myeloma, lym­phoma and prostate cancer. The CLAs ex­pand the com­pa­nies’ pre­vi­ously estab­lish­ed rela­tion­ship, in­clud­ing a service agree­ment signed be­tween Teneobio and Selexis in De­cem­ber 2018.

Through each new CLA, Selexis will provide Teneobio with access to high per­for­mance research cell banks (RCBs) devel­oped using the Selexis SUREtechnology Platform™, with …

Read the full story »

Press Releases»

[ by | Oct 15, 2019 7:45 am | Comments Off ]
  • Ichnos Sciences is a new bio­technology com­pany which is a spin-off of Glenmark Holding SA created to focus on inno­va­tion
  • Pipeline in­cludes five novel, first-in-class clin­i­cal-stage assets in on­col­ogy, auto­immune dis­ease and pain
  • Company assets in­clude: BEAT® (Bispecific Engagement by Antibodies based on the T cell re­cep­tor), a pro­pri­e­tary plat­form; a devel­op­ment site, two research centers; a GMP biologics manu­fac­tur­ing facility and ~350 employees world­wide

Ichnos Sciences Launches As New, Independent, Leading-Edge Biotech Dedicated To Outpacing Disease Paramus, NJ (Press Release) – Ichnos ('īk-nōz) Sciences officially opened its doors to the world today as an independent, fully integrated, global bio­tech com­pany. A spin-off of Glenmark Holding SA, a global pharma­ceu­tical com­pany with a track-record of im­prov­ing patients' lives by providing affordable med­i­cines, the newly formed com­pany was first approved in principle by the Glenmark Board of Directors in Feb­ru­ary 2019 and now operates with its own board of directors …

Read the full story »

Press Releases»

[ by | Sep 16, 2019 8:00 am | Comments Off ]

GBR 1342 to be devel­oped by Glenmark Pharma­ceu­ticals' spinoff inno­va­tion com­pany

Glenmark Receives Orphan Drug Designation For GBR 1342, A Bispecific Antibody Candidate Under Evaluation For The Treatment Of Multiple Myeloma Mahwah, NJ (Press Release) – Glenmark Pharma­ceu­ticals (Glenmark), a research-led, integrated global pharma­ceu­tical com­pany, today announced that the U.S. Food and Drug Admin­istra­tion (FDA) has granted Orphan Drug Desig­na­tion to its bispecific anti­body can­di­date GBR 1342 for the treat­ment of patients with multiple myeloma who have received prior ther­a­pies. Derived from the com­pany's pro­pri­e­tary BEAT® (Bispecific Engagement by Antibodies based on the T cell re­cep­tor) tech­nology, GBR 1342 is being in­ves­ti­gated for the treat­ment of multiple myeloma. The can­di­date is one of five clin­i­cal-stage assets in the pipe­line of Glenmark's new inno­va­tion …

Read the full story »